.jpg)
Spencer talks to to Vered Caplan, CEO at Orgenesis Inc. about how their Point Of Care (POC) Platform aims to shape the Cell and Gene Therapies (CGT) ecosystem and market. Click here to listen.
As the Theranos and Holmes trial finally comes to a close, what has been the effect of the CEO’s 15 years of fraudulent tenure on the diagnostics industry?
.jpg)
In this episode of CM Conversations, our guest share his tips on hitting the ground running and building a team remotely, as well as the importance of investing in relationships. In his words, you should always be visible and available.
In this live webinar, I asked three experienced commercial leaders about their insights, advice and predictions on the future of lateral flow. Click to listen now.
.jpg)
In this live webinar, we asked three experienced commercial leaders about their insights, advice and predictions on the future of this market. Click to watch.
In this episode of CM Conversation, I spoke to Miron Tokarski, CEO of Genomtec, a company operating in the field of clinical diagnostics. Also joining us was Magdalena Kicińska, Marketing Partner at Genomtec. Click to listen to the full episode.
In this clip, I talk about how acting fast is crucial to securing the very best talent in life sciences.
.jpg)
In this clip, I discuss the skills and people that are in demand within the life science industry.
.jpg)
In this clip, I talk about how small companies can beat the larger corporations for talent. They just need to show off what makes them different, that they're people-focused and they can be flexible.
POC diagnostics has played a crucial role in the fight against COVID-19. In this episode of CM Conversations, I speak to Jonathan O’Halloran, who is CEO at QuantuMDx and an industry expert. I ask him: What's next for POC diagnostics?
In this live episode, join life science recruitment experts Eleanor Doolin and Adam Butler as they discuss how the best businesses from across the life science space are winning the war for talent.
.jpg)
Diagnostics still has a crucial role to play in combating COVID-19 and, with new funding, a lot of exciting plans too. To find out more, I spoke to Jonathan O’Halloran, who is CEO at QuantuMDx.
What do you want from diagnostics? Before COVID-19, this wouldn’t have been a question at the forefront of so many peoples' minds. However, now it is and consumers are demanding changes to the industry.
.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
Consistent early detection is considered the 'holy grail' of cancer diagnosis. If you can catch cancer early enough, you can stop it from developing. Liquid biopsy could be the key to unlocking that potential.
.jpg)
The diagnostics space is doing crucial work to detect and limit the spread of Covid-19 all over the world – with companies both big and small contributing to the cause
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
.jpg)
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
As businesses prioritise the wellbeing of their employees, the concept of working a 4 day week is shifting from distant pipedream to reality for a range of organisations around the world.
Even if you’ve been through the process, you may not be aware of exactly what goes into M&A deals. Today, we’ve tried to look into that in a little more detail with Transaction Liability Team Leader Grant Hollis from CFC Underwriting,
The approach to fighting coronavirus has not differed to the fight against any other outbreak in terms of what is required to control it.
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
To find out more about Bond Health, I spoke to Phil Groom, Commercial Director, and Viktoriya Agova, Marketing Manager from Bond Health to hear how they're connecting the world of lateral flow.
.jpg)
COVID-19 is one of the biggest challenges healthcare has ever faced. Crucial work is being done throughout molecular diagnostics to limit the spread in what many would call the space's finest hour.
.png)
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
.png)
While it remains the fourth most common type of cancer for women worldwide, cervical cancer is one of the most preventable and curable with early diagnosis. Let's raise awareness and get more women around the world screened.
NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years ago, the race began…
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
Globally, sepsis takes six million lives each year. It causes more deaths than breast cancer, lung cancer and stroke combined. Here are five diagnostics companies combating this ugly statistic.
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
With a new home, the Minicare I-20 will cement its place as the market leader. As always, this extra competition will encourage innovation among competitors.
Lessons in lateral flow don't come much better than from a founding father of the technology. That's just what we got by speaking with Paul Davis, Co-founder and Chief Scientific Officer at Mologic.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
Whether you call it a lateral flow test, dipstick, rapid test or test strip, they’re all different names for the same sort of test that, in the past, has acquired a somewhat unfair reputation for being too simplistic.
In the world of in vitro diagnostics, there’s nowhere more exciting than Asia. To put it into context, in the period between 2017 and 2022, the North American IVD market is expected to grow from $31.1B to $36.9B,but the Asian market over the same...
Traumatic brain injury (TBI) is a frightening prospect. One reason for this is that concussion doesn’t always present symptoms instantly, it can occur in different people at different times.
Everyone is always developing the next big thing in diagnostics. Whether it’s a blood test to identify a disease earlier than ever, or a point-of-care device that might save thousands of lives in a rural area, the whole market is constantly evolving.
There aren’t many sectors of industry that have seen as much progress in the last 20 years as molecular diagnostics. Point of care testing has, in some cases, eliminated the need for samples to be sent off to labs, enabling physicians to obtain near-
The value of the point-of-care (POC) diagnostics market has been steadily increasing for the past 40 years, but we’ve seen exponential growth in the last 2. POC analysis offers several advantages to laboratory-based tests, given that they are norm...
